Epigenetic "bivalently marked" process of cancer stem cell-driven tumorigenesis

BioEssays

Volumn 29, Issue 9, 2007, Pages 842-845

  Balch, Curt ^a,b   Nephew, Kenneth P ^a,b   Huang, Tim H M ^c   Bapat, Sharmila A ^d  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; PROTEIN BMI 1; PROTEIN POLYCOMB; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GERM CELL TUMOR; HUMAN; PLURIPOTENT STEM CELL; PROTEIN BINDING; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADULT; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMATIN; EMBRYONIC STEM CELLS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; REPRESSOR PROTEINS;

EID: 34548716445     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20619     Document Type: Article

References (30)

1. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. 2007. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39:237-242.
2. Jones PA, Baylin SB. 2007. The epigenomics of cancer. Cell 128:683-692.
3. Goldberg AD, Allis CD, Bernstein E. 2007. Epigenetics: a landscape takes shape. Cell 128:635-638.
4. Reik W, Dean W, Walter J. 2001. Epigenetic reprogramming in mammalian development. Science 293:1089-1093.
5. Azuara V, Perry P, Sauer S, Spivakov M, Jorgensen HF, et al. 2006. Chromatin signatures of pluripotent cell lines. Nat Cell Biol 8:532-538.
6. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, et al. 2006. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315-326.
7. Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, et al. 2006. Dominant-negative histone h3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res 66:5582-5591.
8. Gan Q, Yoshida T, McDonald OG, Owens GK. 2007. Concise review: epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. Stem Cells 25:2-9.
9. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645-648.
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988.
11. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. 2004. Identification of human brain tumour initiating cells. Nature 432:396-401.
12. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. 2005. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65:3025-3029.
13. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, et al. 2006. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 66:3541-3549.
14. Schwartz YB, Pirrotta V. 2007. Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet 8:9-22.
15. Kuzmichev A, Margueron R, Vaquero A, Preissner TS, Scher M, et al. 2005. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 102:1859-1864.
16. Glinsky GV, Berezovska O, Glinskii AB. 2005. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115:1503-1521.
17. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, et al. 2006. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature.
18. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. 2006. Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125:301-313.
19. Kawano Y, Kypta R. 2003. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116:2627-2634.
20. Baylin SB, Ohm JE. 2006. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107-116.
21. Al-Hajj M, Clarke MF. 2004. Self-renewal and solid tumor stem cells. Oncogene 23:7274-7282.
22. Townson JL, Chambers AF. 2006. Dormancy of solitary metastatic cells. Cell Cycle 5:1744-1750.
23. Suzuki M, Mose ES, Montel V, Tarin D. 2006. Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency. Am J Pathol 169:673-681.
24. Beachy PA, Karhadkar SS, Berman DM. 2004. Tissue repair and stem cell renewal in carcinogenesis. Nature 432:324-331.
25. Araki H, Mahmud N, Milhem M, Nunez R, Xu M, et al. 2006. Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents. Exp Hematol 34:140-149.
26. Suzuki M, Harashima A, Okochi A, Yamamoto M, Nakamura S, et al. 2004. 5-Azacytidine supports the long-term repopulating activity of cord blood CD34(+) cells. Am J Hematol 77:313-315.
27. Tsuji-Takayama K, Inoue T, Ijiri Y, Otani T, Motoda R, et al. 2004. Demethylating agent, 5-azacytidine, reverses differentiation of embryonic stem cells. Biochem Biophys Res Commun 323:86-90.
28. Jones PA, Taylor SM. 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93.
29. Marks PA, Breslow R. 2007. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90.
30. Yoo CB, Jones PA. 2006. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37-50.